Vaccine and immunotherapy for KRAS-mutated lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This Phase 1 study tests a KRAS-targeted vaccine combined with chemo and immunotherapy (nivolumab and ipilimumab) for people with advanced non-small cell lung cancer. It aims to help the immune system recognize and fight tumors with specific KRAS mutations, and to see if the treatment is safe and effective enough to study further.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have non-small cell lung cancer that is advanced, not operable, or has spread (metastatic), and you have not had treatment for this stage before.
- Your tumor has a KRAS mutation the vaccine targets (specific types like G12C, G12V, G12D, G12A, G13D, or G12R), confirmed by approved genetic testing of tumor tissue or blood.
- You can have tumor biopsies taken more than once (at the start and during treatment) from a reachable spot, and you agree to them if the doctor feels it’s safe.
- Your cancer has measurable disease on scans, and you are physically well enough (ECOG 0 or 1).
- You have adequate blood and organ health (for example: platelets and white blood cells are above minimum levels, liver and kidney tests are within limits).
- You are able and willing to sign consent and follow study visits and treatment schedule, including staying off certain medicines and vaccines around treatment time.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental drug (RX001) given directly into tumors for people with advanced lung cancer that has a KRAS mutation. It is a phase 1 trial, so the main goal is to check safety and find a good dose.
This trial tests a new drug, VS-7375, for people with advanced non-small cell lung cancer that has a specific genetic change called KRAS G12D. It's for those who have already tried chemo and immunotherapy, and whose cancer has continued to grow.
This trial tests two new targeted drugs (IN10018 and D-1553) together as a first treatment for advanced non-squamous lung cancer with a specific KRAS G12C mutation. It compares this combination to standard therapy to see if it works better.
This trial tests a cancer vaccine designed to target KRAS-mutated tumors, combined with two immunotherapy drugs, for people with advanced colorectal or pancreatic cancer. It may help the immune system recognize and attack cancer cells.
This trial tests a cancer vaccine (ELI-002 7P) for people with pancreatic cancer that hasn't spread to other parts of the body. It may be given alone or with another drug (tislelizumab) that helps the immune system fight cancer. The goal is to see if these treatments can help keep the cancer from coming back after surgery or chemotherapy.
This trial tests a vaccine designed to target cancers with KRAS mutations. It may be an option if your cancer has a KRAS mutation and you have either tried other treatments without success or have a newly diagnosed, early-stage lung adenocarcinoma.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.